Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. reports developments tied to its clinical-stage biotherapeutics platform for oral delivery of biologics and drugs. The company’s RaniPill® capsule technology is designed to deliver drug substances such as antibodies, proteins, peptides and oligonucleotides as an alternative to subcutaneous injection or intravenous infusion.
Recurring RANI news includes clinical and preclinical updates for RaniPill-based programs, including RT-114, a GLP-1/GLP-2 dual agonist program for obesity, and oral semaglutide work. Company updates also cover financial results, collaboration and license activity, private placement financing, manufacturing and supply-chain capabilities, pipeline prioritization, investor conference participation, and leadership or advisory appointments supporting platform and clinical strategy.
Rani Therapeutics (Nasdaq: RANI) reported second quarter 2026 results and clinical and corporate milestones. The company highlighted positive initial Phase 1a data for RT-114, where oral delivery via the RaniPill Capsule™ achieved bioavailability greater than 150% versus matched subcutaneous PG-102, with similar elimination half-life and no serious adverse events.
Rani began dosing participants in a Phase 1a expansion cohort of RT-114 and plans to initiate a Phase 1b repeat-dose obesity study by end of 2026, with data expected in 2027. It entered a research and development collaboration with PegBio on oral obesity and metabolic candidates, completed a $20 million registered direct offering, and appointed Nicholas Maestas as CFO and Michelle Gilson to its Board. Cash, cash equivalents and marketable securities were $53.4 million as of June 30, 2026, and Rani expects funding to last at least through 2027. Q2 2026 contract revenue was $1.7 million and net loss was $8.4 million, improved from $11.2 million a year earlier.
Rani Therapeutics (Nasdaq: RANI) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 2:30 p.m. ET in Boston, MA. The Chief Executive Officer, Talat Imran, and Chief Financial Officer, Nicholas Maestas, will deliver a presentation and hold 1x1 meetings. A live webcast and replay will be available via the Investor Relations section of the company’s website.
Rani Therapeutics (Nasdaq:RANI) has appointed Michelle Gilson to its Board of Directors, where she will serve as Chair of the Audit Committee. The clinical-stage biotherapeutics company focuses on oral delivery of biologics using its RaniPill technology.
According to Rani Therapeutics, Gilson most recently served as Chief Financial Officer of Arcellx, which was acquired by Gilead in 2026, and played key roles in Arcellx's financial strategy, BLA-stage scaling, and collaboration with Kite. She previously worked as a biotechnology equity research analyst at several major investment banks and holds a B.S. in Business Administration from the University of Southern California.
Rani Therapeutics (Nasdaq: RANI) disclosed an inducement stock option grant to new Chief Financial Officer Nicholas Maestas under Nasdaq Listing Rule 5635(c)(4). The option covers 2,000,000 shares of Class A common stock, granted on July 17, 2026, with an exercise price of $0.6973 per share, equal to the closing price on the grant date.
The option has a ten-year term and vests over four years: 25% on the one-year anniversary of employment commencement and the remainder in equal monthly installments over the following 36 months, subject to continued service. The grant was approved by the Board’s Compensation Committee under Rani’s 2026 Equity Inducement Plan.
Rani Therapeutics (Nasdaq: RANI) reported positive initial Phase 1a data for RT-114, an orally administered RaniPill® Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist for obesity and metabolic disease. In 30 healthy volunteers, a single 12 mg oral dose of RT-114 achieved systemic exposure and bioavailability >150% versus a matched 12 mg subcutaneous PG-102 injection.
No serious adverse events occurred in either arm, and no adverse events were attributed to the RaniPill® Capsule; treatment-related events such as nausea, vomiting and diarrhea were mild, transient and consistent with the GLP-1/GLP-2 agonist class. Elimination half-life was similar between routes (5.6 days oral vs 5.3 days subcutaneous).
Rani is expanding the Phase 1a study with an additional cohort of 15 healthy volunteers, each receiving two 12 mg oral doses (24 mg total) to further characterize the oral-to-subcutaneous pharmacokinetic relationship. These data are expected to guide dose selection for a planned Phase 1b repeat-dose study in patients with obesity, anticipated to start in 2026 with data expected in 2027.
Rani Therapeutics (Nasdaq:RANI) announced a research and development collaboration with PegBio to explore oral delivery of multiple novel obesity and metabolic disease molecules using the RaniPill® platform.
The agreement focuses on preclinical RaniPill formulations, aiming to advance the most promising candidates into clinical development and further expand Rani's obesity franchise, which already includes RT-114 in Phase 1 and preclinical semaglutide data.
Rani Therapeutics (Nasdaq:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, appointed Nicholas Maestas as Chief Financial Officer, effective immediately.
He brings 10+ years of biotech finance experience, including roles at Tempest Therapeutics, Alector and Immune Design, and will support the RaniPill® oral delivery platform strategy.
Rani Therapeutics (Nasdaq:RANI) priced a registered direct offering of Class A common stock and pre-funded warrants, at-the-market under Nasdaq rules, expected to raise about $20.0 million in gross proceeds.
The deal includes 12,476,637 shares at $1.07 and 6,214,953 pre-funded warrants at $1.0699, closing around May 27, 2026.
Rani Therapeutics (Nasdaq:RANI) reported first quarter 2026 results and leadership updates. Cash, cash equivalents and marketable securities were $43.4 million on March 31, 2026, with funding expected into Q4 2027. Contract revenue rose to $1.7 million, while net loss narrowed to $8.0 million. Rani advanced its Phase 1 obesity candidate RT-114 via RaniPill®, promoted Alireza Javadi to Chief Technical Officer, and appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor. The company announced a planned Chief Financial Officer transition as it searches for a successor.
Rani Therapeutics (Nasdaq:RANI) announced that its management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, at 10:00 a.m. ET.
The CEO and CFO will join a fireside chat and 1x1 meetings, with a live and replay webcast available via the company’s investor relations website.